comparemela.com

Latest Breaking News On - Algernon pharmaceuticals inc - Page 3 : comparemela.com

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Japan
Canada
Vancouver
British-columbia
United-kingdom
China
Canadian
Japanese
British
Christopherj-moreau
Japanese-patent-office

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023

Algernon Pharmaceuticals Inc. reported earnings results for the full year ended August 31, 2023. For the full year, the company reported net loss was CAD 6.78 million compared to CAD 6.05 million a.

Algernon-pharmaceuticals-inc
Algernon-pharmaceuticals
Markets

Algernon Pharmaceuticals Announces Closing of Private Placement

Algernon Pharmaceuticals Announces Closing of Private Placement
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Canada
Vancouver
British-columbia
United-kingdom
Canadian
British
Christopherj-moreau
No-securities-exchange
Algernon-pharmaceuticals-announces-closing-of-private-placement
Algernon-pharmaceuticals-inc
Company-or-algernona-canadian

Algernon Pharmaceuticals Announces Closing of Private Placement

Algernon Pharmaceuticals Announces Closing of Private Placement
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Canada
Vancouver
British-columbia
New-york
United-states
Ottawa
Ontario
British
Canadian
Joe-oconnor
Ted-rechtshtaffen

vimarsana © 2020. All Rights Reserved.